Advertisement

Advances in Therapy

, Volume 26, Issue 8, pp 795–804 | Cite as

Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial

  • Mark A. MoyadEmail author
  • Larry E. Robinson
  • Julie M. Kittelsrud
  • Stuart G. Reeves
  • Susan E. Weaver
  • Aireen I. Guzman
  • Mark E. Bubak
Open Access
Original Research

Abstract

Introduction

Allergic rhinitis (AR) impacts around 25% of the worldwide population. However, cost, safety, and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion. Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound; therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms.

Methods

A 12-week, randomized, double-blind, placebo-controlled clinical trial of 96 healthy subjects with a recent clinically documented history of seasonal allergies and AR was conducted. Participants received once-daily supplementation with 500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product (EpiCor®, Embria Health Sciences, Ankeny, Iowa, USA) or placebo during the 12-week period of the highest recorded concentrations of total pollen counts for this Midwest geographic area. Clinical outcome measurements included in-clinic examinations, validated questionnaire and standard diary, and serologic analysis at baseline, 6 and 12 weeks.

Results

During the highest pollen count period (weeks 1–6), EpiCor significantly reduced the mean severity of specific AR symptoms, including a significant reduction in nasal congestion (P=0.04), rhinorrhea (P=0.005), and a nonsignificant reduction in ocular discharge symptoms. A significantly (P=0.04) reduced total number of days with nasal congestion (12.5 fewer days) favored EpiCor compared with placebo, as did the nasal congestion section of the quality of life questionnaire (P=0.04). Subjects receiving the intervention also experienced significantly (P=0.03) higher salivary IgA levels. Adverse events were similar to placebo.

Conclusion

This yeast-derived product appeared to be safe and efficacious, and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion.

Keywords

allergic rhinitis dietary supplement EpiCor® nasal congestion Saccharomyces cerevisiae seasonal allergy 

References

  1. 1.
    van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement for the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000; 55:116–134.CrossRefGoogle Scholar
  2. 2.
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004; 24:758–764.PubMedCrossRefGoogle Scholar
  3. 3.
    Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection and diagnosis. J Allergy Clin Immunol. 2001; 108:2–8.CrossRefGoogle Scholar
  4. 4.
    Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group: World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108(suppl. 5):S147–S334.PubMedCrossRefGoogle Scholar
  5. 5.
    D’Alonzo GE Jr. Scope and impact of allergic rhinitis. J Am Osteopath Assoc. 2002; 102(suppl. 2):S2–S6.PubMedGoogle Scholar
  6. 6.
    McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy. 1994; 73:35–39.PubMedGoogle Scholar
  7. 7.
    Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. Vital Health Stat. 2006; 13:1–66.Google Scholar
  8. 8.
    Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Man Care. 1998; 4:89–96.Google Scholar
  9. 9.
    Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006; 22:1203–1210.PubMedCrossRefGoogle Scholar
  10. 10.
    Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998; 81:463–468.PubMedGoogle Scholar
  11. 11.
    Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manage Care. 2000; 6:373–378.Google Scholar
  12. 12.
    US Department of Health and Human Services web site. Agency for Healthcare Research and Quality. Management of Allergic and Nonallergic Rhinitis: Summary. Evidence Report/Technology Assessment 54. May 2002. Available at: http://www.ahrq.gov/clinic/epcsums/rhinsum.htm. Accessed July 2009.
  13. 13.
    Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005; 4:439–446.PubMedCrossRefGoogle Scholar
  14. 14.
    Allergies in America: a landmark survey of nasal allergy sufferers: executive summary. Florham Park, NJ: Altana Pharma US, Inc; 2006. Available at: http://www.myallergiesinamerica.com. Accessed June 1, 2009.
  15. 15.
    Santos CB, Pratt EL, Hanks C, et al. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol. 2006; 97:579–586.PubMedGoogle Scholar
  16. 16.
    Sundberg R, Toren K, Hoglund D, et al. Nasal symptoms are associated with school performance in adolescents. J Adolesc Health. 2007; 40:581–583.PubMedCrossRefGoogle Scholar
  17. 17.
    Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007; 28:3–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Moyad MA, Robinson LE, Zawada ET Jr., et al. Effects of a modified yeast supplement on cold/flu symptoms. Urol Nurs. 2008; 28:50–55.PubMedGoogle Scholar
  19. 19.
    Jensen GS, Patterson KM, Barnes J, et al. A doubleblind placebo-controlled, randomized pilot study: consumption of a high metabolite immunogen from yeast culture has beneficial effects on erythrocyte health and mucosal immune protection in healthy subjects. Open Nutr J. 2008; 2:68–75.CrossRefGoogle Scholar
  20. 20.
    Nathan RA. The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther. 2008; 30:573–586.PubMedCrossRefGoogle Scholar
  21. 21.
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991; 21:77–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005; 115:S390–S413.PubMedCrossRefGoogle Scholar
  23. 23.
    Stewart MG. Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children. Clin Exp Allergy. 2008; 38:751–760.PubMedCrossRefGoogle Scholar
  24. 24.
    Stokes J, Fenstad E, Casale TB. Managing impairment in patients with allergic rhinitis. Allergy Asthma Proc. 2006; 27:12–16.PubMedGoogle Scholar
  25. 25.
    Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc. 2007; 28:10–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Passalacqua G, Bousquet PJ, Carlsen K-H, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006; 117:1054–1062.PubMedCrossRefGoogle Scholar
  27. 27.
    Man LX. Complementary and alternative medicine for allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 2009; 17:226–231.PubMedCrossRefGoogle Scholar
  28. 28.
    Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2007; 99:483–495.PubMedCrossRefGoogle Scholar
  29. 29.
    Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol. 2009; 123:283–294.PubMedCrossRefGoogle Scholar
  30. 30.
    Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol. 2004; 114:S146–S153.PubMedCrossRefGoogle Scholar
  31. 31.
    Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med. 2008; 8:437–445.PubMedCrossRefGoogle Scholar
  32. 32.
    Magen E, Yosefy C, Viskoper RJ, Mishal J, Treatment of allergic rhinitis can improve blood pressure control. J Hum Hypertens. 2006; 20:888–893.PubMedCrossRefGoogle Scholar
  33. 33.
    Qian FH, Zhang Q, Zhou LF, et al. High-sensitivity C-reactive protein: a predictive marker in severe asthma. Respirology. 2008; 13:664–669.PubMedCrossRefGoogle Scholar
  34. 34.
    Naclerio RM, Adkinson NF, Creticos PS, et al. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J Allergy Clin Immunol. 1993; 92:717–721.PubMedCrossRefGoogle Scholar
  35. 35.
    Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg. 2008; 138:129–139.PubMedCrossRefGoogle Scholar
  36. 36.
    Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med. 2005; 353:1934–1944.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Mark A. Moyad
    • 1
    Email author
  • Larry E. Robinson
    • 2
  • Julie M. Kittelsrud
    • 3
  • Stuart G. Reeves
    • 4
  • Susan E. Weaver
    • 3
  • Aireen I. Guzman
    • 5
  • Mark E. Bubak
    • 6
  1. 1.Preventive & Alternative MedicineUniversity of Michigan Medical Center, Department of UrologyAnn ArborUSA
  2. 2.Scientific AffairsEmbria Health SciencesAnkenyUSA
  3. 3.Avera Research InstituteSioux FallsUSA
  4. 4.Research and DevelopmentEmbria Health SciencesAnkenyUSA
  5. 5.Avera Research InstituteSioux FallsUSA
  6. 6.Allergy, Department of Internal MedicineUSD Sanford School of MedicineSioux FallsUSA

Personalised recommendations